Robert John Moots
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert John Moots has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Nicola J. Goodson
Department of Rheumatology, Aintree University Hospitals NHS Trust, Liverpool, UK
10 shared publications - Sizheng Steven Zhao
Centre for Musculoskeletal Research, The University of Manchester
10 shared publications David M Hughes
Department of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool
5 shared publicationsFarida Fortune
Queen Mary University of London, UK; Barts Health NHS Trust, The London Hospital , London UK
5 shared publications- Gareth T. Jones
University of Aberdeen, Aberdeen, UK
5 shared publications - Helen Louise Wright
Institute of Life Course and Medical Sciences, University of Liverpool , Liverpool
5 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 22 (9) , 975-988
Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review
1. Biologic therapies have been used successfully to treat many conditions, but are often associated with high costs due in part to the complexity of drug development [1,2]. After patent expiry and...
- 2 September 2026
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 22 (9) , 975-988
Open AccessSwitchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review
1. Biologic therapies have been used successfully to treat many conditions, but are often associated with high costs due in part to the complexity of drug development [1,2]. After patent expiry and...
- Open Access
- 1 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (10) , 964-965
Developing Rheumatology in Sub-Saharan Africa: Addressing the Challenges
- 1 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (10) , 964-965
Open AccessDeveloping Rheumatology in Sub-Saharan Africa: Addressing the Challenges
- Open Access
- 1 June 2025
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 6 (2) , 70-79
Predicting response to infliximab and interferon-α in Behçet’s syndrome: An exploratory analysis from the BIO-BEHÇET’S randomized controlled trial
Background and Objectives: Biologic therapy has been used for Behçet’s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEHÇET’S was a randomized controlled clinical trial to compare the two most widely used biologics for Behçet’s Syndrome at that time, infliximab versus interferon-α2a, and identify potential biomarkers for response. Methods: A total of 79 patients with active Behçet’s Syndrome were randomized to either infliximab (REMICADE) or interferon-α2a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in IFNL3 and IFNL4 – selected based on known effects – impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis. Results: Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the IFNL3 (IL-28B) gene locus for interferon-α2a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab. Conclusion: BIO-BEHÇET’S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet’s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.
- 1 June 2025
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 6 (2) , 70-79
Open AccessPredicting response to infliximab and interferon-α in Behçet’s syndrome: An exploratory analysis from the BIO-BEHÇET’S randomized controlled trial
Background and Objectives: Biologic therapy has been used for Behçet’s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEHÇET’S was a randomized controlled clinical trial to compare the two most widely used biologics for Behçet’s Syndrome at that time, infliximab versus interferon-α2a, and identify potential biomarkers for response. Methods: A total of 79 patients with active Behçet’s Syndrome were randomized to either infliximab (REMICADE) or interferon-α2a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in IFNL3 and IFNL4 – selected based on known effects – impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis. Results: Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the IFNL3 (IL-28B) gene locus for interferon-α2a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab. Conclusion: BIO-BEHÇET’S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet’s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.
- Open Access
- 1 December 2024
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 5 (4) , 186-188
The potential for biosimilars to address unmet clinical need — Is the developed world missing out?
Article The potential for biosimilars to address unmet clinical need — Is the developed world missing out? was published on December 1, 2024 in the journal Rheumatology and Immunology Research (volume 5, issue 4).
- 1 December 2024
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 5 (4) , 186-188
Open AccessThe potential for biosimilars to address unmet clinical need — Is the developed world missing out?
Article The potential for biosimilars to address unmet clinical need — Is the developed world missing out? was published on December 1, 2024 in the journal Rheumatology and Immunology Research (volume 5, issue 4).
- 21 October 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2882-2891
Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial
Objectives: Whilst biologic therapy is used for Behçet’s syndrome of all subtypes refractory to first-line immunomodulation, there has been an absence of high-quality evidence and no predictive biomarkers to optimally inform choice. BIO-BEHÇET’S was a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Methods: This was a Bayesian-designed, pragmatic, standard of care, two-arm, parallel head-to-head trial at four UK centres. Patients with active disease were randomized to infliximab or IFN-α2a, and received follow-up with symptom-directed examination at weeks 12 and 24. The primary outcome was the Behçet’s Disease Activity Index (BDAI) at 12 weeks. Secondary outcomes included BDAI at 24 weeks and significant improvement in individual organ systems, including ocular symptoms, oral and genital ulcers, arthritis pain, quality of life, disease activity and steroid use. Biomarkers were also investigated but are reported elsewhere. Results: Seventy-nine patients were recruited. Both treatments were equally effective, with a mean difference of 0.13 in BDAI (80% confidence interval: –0.19, 0.46). No significant differences were observed for secondary outcomes, though there were clinically significant within-group reductions for each over time. A modest steroid-sparing effect was observed, with complete cessation of steroids in 20% and 44% of those randomized to infliximab and IFN-α2a, respectively. There was a trend for minor benefit in favour of infliximab in terms of tolerability and persistence. Conclusion: In this first reported, high-quality, head-to-head trial of two biologics in Behçet’s, both infliximab and IFN-α2a showed comparable short-term clinical efficacy and safety in refractory active disease of all subtypes. Trial registration: EudraCT: 2014–005390-36; ISRCTN: ISRCTN49793874
- 21 October 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2882-2891
Infliximab vs interferon-α in the treatment of Behçet’s syndrome: clinical data from the BIO-BEHÇET’S randomized controlled trial
Objectives: Whilst biologic therapy is used for Behçet’s syndrome of all subtypes refractory to first-line immunomodulation, there has been an absence of high-quality evidence and no predictive biomarkers to optimally inform choice. BIO-BEHÇET’S was a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Methods: This was a Bayesian-designed, pragmatic, standard of care, two-arm, parallel head-to-head trial at four UK centres. Patients with active disease were randomized to infliximab or IFN-α2a, and received follow-up with symptom-directed examination at weeks 12 and 24. The primary outcome was the Behçet’s Disease Activity Index (BDAI) at 12 weeks. Secondary outcomes included BDAI at 24 weeks and significant improvement in individual organ systems, including ocular symptoms, oral and genital ulcers, arthritis pain, quality of life, disease activity and steroid use. Biomarkers were also investigated but are reported elsewhere. Results: Seventy-nine patients were recruited. Both treatments were equally effective, with a mean difference of 0.13 in BDAI (80% confidence interval: –0.19, 0.46). No significant differences were observed for secondary outcomes, though there were clinically significant within-group reductions for each over time. A modest steroid-sparing effect was observed, with complete cessation of steroids in 20% and 44% of those randomized to infliximab and IFN-α2a, respectively. There was a trend for minor benefit in favour of infliximab in terms of tolerability and persistence. Conclusion: In this first reported, high-quality, head-to-head trial of two biologics in Behçet’s, both infliximab and IFN-α2a showed comparable short-term clinical efficacy and safety in refractory active disease of all subtypes. Trial registration: EudraCT: 2014–005390-36; ISRCTN: ISRCTN49793874
- 1 September 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (9) , 1145-1156
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis
Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. To assess symptomatic benefits of methotrexate in knee OA (KOA). A multicenter, randomized, double-blind, placebo-controlled trial done between 13 June 2014 and 13 October 2017. (ISRCTN77854383; EudraCT: 2013-001689-41). 15 secondary care musculoskeletal clinics in the United Kingdom. A total of 207 participants with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months with inadequate response to current medication were approached for inclusion. Participants were randomly assigned 1:1 to oral methotrexate once weekly (6-week escalation 10 to 25 mg) or matched placebo over 12 months and continued usual analgesia. The primary end point was average knee pain (numerical rating scale [NRS] 0 to 10) at 6 months, with 12-month follow-up to assess longer-term response. Secondary end points included knee stiffness and function outcomes and adverse events (AEs). A total of 155 participants (64% women; mean age, 60.9 years; 50% Kellgren-Lawrence grade 3 to 4) were randomly assigned to methotrexate (n = 77) or placebo (n = 78). Follow-up was 86% (n = 134; methotrexate: 66, placebo: 68) at 6 months. Mean knee pain decreased from 6.4 (SD, 1.80) at baseline to 5.1 (SD, 2.32) at 6 months in the methotrexate group and from 6.8 (SD, 1.62) to 6.2 (SD, 2.30) in the placebo group. The primary intention-to-treat analysis showed a statistically significant pain reduction of 0.79 NRS points in favor of methotrexate (95% CI, 0.08 to 1.51; P = 0.030). There were also statistically significant treatment group differences in favor of methotrexate at 6 months for Western Ontario and McMaster Universities Osteoarthritis Index stiffness (0.60 points [CI, 0.01 to 1.18]; P = 0.045) and function (5.01 points [CI, 1.29 to 8.74]; P = 0.008). Treatment adherence analysis supported a dose-response effect. Four unrelated serious AEs were reported (methotrexate: 2, placebo: 2). Not permitting oral methotrexate to be changed to subcutaneous delivery for intolerance. Oral methotrexate added to usual medications demonstrated statistically significant reduction in KOA pain, stiffness, and function at 6 months. Versus Arthritis.
- 1 September 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (9) , 1145-1156
Pain Reduction With Oral Methotrexate in Knee Osteoarthritis
Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. To assess symptomatic benefits of methotrexate in knee OA (KOA). A multicenter, randomized, double-blind, placebo-controlled trial done between 13 June 2014 and 13 October 2017. (ISRCTN77854383; EudraCT: 2013-001689-41). 15 secondary care musculoskeletal clinics in the United Kingdom. A total of 207 participants with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months with inadequate response to current medication were approached for inclusion. Participants were randomly assigned 1:1 to oral methotrexate once weekly (6-week escalation 10 to 25 mg) or matched placebo over 12 months and continued usual analgesia. The primary end point was average knee pain (numerical rating scale [NRS] 0 to 10) at 6 months, with 12-month follow-up to assess longer-term response. Secondary end points included knee stiffness and function outcomes and adverse events (AEs). A total of 155 participants (64% women; mean age, 60.9 years; 50% Kellgren-Lawrence grade 3 to 4) were randomly assigned to methotrexate (n = 77) or placebo (n = 78). Follow-up was 86% (n = 134; methotrexate: 66, placebo: 68) at 6 months. Mean knee pain decreased from 6.4 (SD, 1.80) at baseline to 5.1 (SD, 2.32) at 6 months in the methotrexate group and from 6.8 (SD, 1.62) to 6.2 (SD, 2.30) in the placebo group. The primary intention-to-treat analysis showed a statistically significant pain reduction of 0.79 NRS points in favor of methotrexate (95% CI, 0.08 to 1.51; P = 0.030). There were also statistically significant treatment group differences in favor of methotrexate at 6 months for Western Ontario and McMaster Universities Osteoarthritis Index stiffness (0.60 points [CI, 0.01 to 1.18]; P = 0.045) and function (5.01 points [CI, 1.29 to 8.74]; P = 0.008). Treatment adherence analysis supported a dose-response effect. Four unrelated serious AEs were reported (methotrexate: 2, placebo: 2). Not permitting oral methotrexate to be changed to subcutaneous delivery for intolerance. Oral methotrexate added to usual medications demonstrated statistically significant reduction in KOA pain, stiffness, and function at 6 months. Versus Arthritis.
- Open Access
- 10 July 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1383-1392
Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis
Introduction High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-modifying antirheumatic drug (csDMARD) triple therapy. Datasets from three randomized clinical trials in patients with RA were used to test the hypothesis that baseline NLR is associated with improved clinical response to filgotinib in methotrexate (MTX)-naïve or MTX-experienced RA populations. Methods Patients from FINCH 1 (inadequate response to MTX, MTX-IR; NCT02889796), FINCH 2 (inadequate response to biologic DMARDs; NCT02873936), and FINCH 3 (MTX-naïve; NCT02886728) were classified as baseline NLR-High or baseline NLR-Low based on a previously published cut point of 2.7. In total, 3365 patients were included across the three studies. Differences in clinical outcomes and patient-reported outcomes (PROs) were determined using linear-regression models. Results Control-arm patients (placebo + MTX/placebo + csDMARD) classified as NLR-High exhibited worse continuous clinical and PRO responses at week 12 across clinical trials compared to NLR-Low patients. In contrast, NLR-High patients who received FIL 200 mg + MTX/csDMARD exhibited consistently better responses after 12 weeks compared to NLR-Low patients across clinical trials, clinical endpoints, and PROs. These trends were most prominent among the MTX-IR population. Conclusion The 2.7 baseline NLR cut point could be used to enrich for patients most likely to benefit from the addition of filgotinib to background MTX/csDMARD. Use of baseline NLR as part of therapeutic decision-making would not require additional diagnostics and could contribute to improved outcomes for patients with RA. Trial Registration Clinicaltrials.gov: NCT02889796; NCT02873936; NCT02886728.
- 10 July 2024
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (5) , 1383-1392
Open AccessPatients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis
Introduction High baseline neutrophil-to-lymphocyte ratio (NLR) in rheumatoid arthritis (RA) has been associated with positive responses to biologic tumor necrosis factor inhibition and negative responses to conventional synthetic disease-modifying antirheumatic drug (csDMARD) triple therapy. Datasets from three randomized clinical trials in patients with RA were used to test the hypothesis that baseline NLR is associated with improved clinical response to filgotinib in methotrexate (MTX)-naïve or MTX-experienced RA populations. Methods Patients from FINCH 1 (inadequate response to MTX, MTX-IR; NCT02889796), FINCH 2 (inadequate response to biologic DMARDs; NCT02873936), and FINCH 3 (MTX-naïve; NCT02886728) were classified as baseline NLR-High or baseline NLR-Low based on a previously published cut point of 2.7. In total, 3365 patients were included across the three studies. Differences in clinical outcomes and patient-reported outcomes (PROs) were determined using linear-regression models. Results Control-arm patients (placebo + MTX/placebo + csDMARD) classified as NLR-High exhibited worse continuous clinical and PRO responses at week 12 across clinical trials compared to NLR-Low patients. In contrast, NLR-High patients who received FIL 200 mg + MTX/csDMARD exhibited consistently better responses after 12 weeks compared to NLR-Low patients across clinical trials, clinical endpoints, and PROs. These trends were most prominent among the MTX-IR population. Conclusion The 2.7 baseline NLR cut point could be used to enrich for patients most likely to benefit from the addition of filgotinib to background MTX/csDMARD. Use of baseline NLR as part of therapeutic decision-making would not require additional diagnostics and could contribute to improved outcomes for patients with RA. Trial Registration Clinicaltrials.gov: NCT02889796; NCT02873936; NCT02886728.
- 30 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 952-962
The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial
- 30 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 952-962
The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial
- Open Access
- 16 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (11) , 3516-3517
Cutaneous signs of rheumatic diseases in skin of colour: are we failing our patients?
Jonathan Haddad, Ian Coulson, G Omondi Oyoo, Robert J Moots; Cutaneous signs of rheumatic diseases in skin of colour: are we failing our patients?, Rheumatology
- 16 May 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (11) , 3516-3517
Open AccessCutaneous signs of rheumatic diseases in skin of colour: are we failing our patients?
Jonathan Haddad, Ian Coulson, G Omondi Oyoo, Robert J Moots; Cutaneous signs of rheumatic diseases in skin of colour: are we failing our patients?, Rheumatology
- Open Access
- 1 March 2023
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 4 (1) , 1-3
The challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care?
Article The challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care? was published on March 1, 2023 in the journal Rheumatology and Immunology Research (volume 4, issue 1).
- 1 March 2023
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 4 (1) , 1-3
Open AccessThe challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care?
Article The challenge of ocular inflammation in systemic vasculitis: How to address inequalities of care? was published on March 1, 2023 in the journal Rheumatology and Immunology Research (volume 4, issue 1).